Chen et al. reported that the c-Myc inhibitor 10058-F4 could work synergistically with Doxo treatment to inhibit the proliferation of drug-resistant cells and promote their apoptosis in triple-negative breast cancer (TNBC) [16]. Here, MYC is linked to triple-negative breast carcinoma.